Special Spring 2026Special: Lab automation + data scienceLaboratory automation is evolving fast. What used to be a patchwork of isolated device solutions has steadily moved toward smarter, interconnected labs. And now that robotics is pushing the field one … more ➔
Special Spring 2026Special: CDMO Landscape EuropeToday, 90% of biotechs outsource manufacturing to CDMOs. Outsourcing decisions are no longer straightforward cost-benefit analyses. Geopolitical volatility and unprecedented demand for advanced modalities … more ➔
Special Summer 2026Preview: Drug Delivery ServicesThe special issue Drug Delivery Services of European Biotechnology Magazine on the occasion of Drug Discovery 2026 in London. more ➔
Special Winter 2025Euro BioFairs CompassGuide to European Life Sciences Events in the first half year of 2026 more ➔
Special Autumn 2025CDMOs & CROsThe Trump administration’s trade policy has hit CDMOs and CROs hard. Trade barriers against Chinese service providers and raw material suppliers have increased biologics production costs and caused … more ➔
Special Summer 2025Euro BioFairs CompassGuide to Life Sciences Events in the second half year of 2025 more ➔
Special Summer 2025(Bio)EngineeringRegions and industry leaders are already preparing for the future. This Special spotlights emerging open innovation clusters and cutting-edge bioengineering platforms. more ➔
Special Spring 2025Oligonucleotides and PeptidesPeptide drugs recorded global sales in Europe. The market for gene and cell therapy contract manufacturing, oligonucleotide synthesis and the production of viral vectors and plasmids is also expanding … more ➔
Special Winter 2024Protein Engineering and ServicesMonoclonal antibodies still dominate the US$417bn biologics market. After decades of development, however, improved antibodies and protein formats with better target selectivity and safety profiles … more ➔
Special Autumn 2024CDMOs & CROsA draft US Biosecure Act being passed by the US House of Representatives and discussed by the US Senate could prohibit US biotech developers from collaborating with Chinese CROs, CDMOs and drug developers … more ➔
